Bristol Myers' Opdivo Scores European Approval As Adjuvant Treatment For Gastric Cancer

The European Commission (EC) has approved Bristol Myers Squibb & Co's BMY Opdivo (nivolumab) as adjuvant treatment of adult patients with esophageal or gastroesophageal junction (GEJ) cancer.
The approval covers patients who have residual pathologic disease following prior neoadjuvant chemoradiotherapy (CRT).
The EC's decision is based on results from the Phase 3 CheckMate -577 trial, which demonstrated that treatment with Opdivo following neoadjuvant CRT and complete surgical resection doubled the primary endpoint of disease-free survival, compared to placebo in the all-randomized population.
Price Action: BMY shares closed at $68.15 on Thursday.
Related content: Benzinga's Full FDA Calendar.

Momentum43.95

Growth70.95

QualityNot Available

Value29.62

Short

Medium

Long